- Report
- March 2024
- 123 Pages
Global
From €7029EUR$7,950USD£6,068GBP
- Report
- April 2023
- 120 Pages
Global
From €4200EUR$4,750USD£3,626GBP
- Report
- April 2023
- 147 Pages
Global
From €4376EUR$4,949USD£3,778GBP
- Report
- April 2023
- 147 Pages
Global
From €4376EUR$4,949USD£3,778GBP
- Drug Pipelines
- June 2022
- 101 Pages
Global
From €13258EUR$14,995USD£11,446GBP
- Drug Pipelines
- June 2023
- 150 Pages
Global
From €13258EUR$14,995USD£11,446GBP
- Report
- July 2024
- 268 Pages
China
From €3537EUR$4,000USD£3,053GBP
- Report
- July 2024
- 141 Pages
China
From €1591EUR$1,800USD£1,374GBP
- Report
- October 2023
- 26 Pages
Global
€10831EUR$12,250USD£9,350GBP
- Report
- August 2022
- 51 Pages
Global
From €1768EUR$2,000USD£1,527GBP
- Report
- October 2024
- 81 Pages
Global
From €3500EUR$4,241USD£3,127GBP
- Report
- October 2023
- 112 Pages
Global
From €3500EUR$4,241USD£3,127GBP
- Report
- October 2023
- 112 Pages
Global
From €3500EUR$4,241USD£3,127GBP
- Report
- May 2023
- 91 Pages
Global
From €3500EUR$4,241USD£3,127GBP
- Book
- March 2022
- 992 Pages
- Book
- January 2010
- 616 Pages
- Book
- October 2010
- 408 Pages
- Book
- March 2015
- 512 Pages
- Book
- August 2014
- 392 Pages
The antiarrhythmic market is a subset of the cardiovascular drug market, which includes drugs used to treat abnormal heart rhythms. Antiarrhythmic drugs are used to treat arrhythmias, which are abnormal heart rhythms that can cause symptoms such as palpitations, dizziness, and chest pain. These drugs work by blocking or slowing down electrical signals in the heart, restoring the normal rhythm. Common types of antiarrhythmic drugs include beta blockers, calcium channel blockers, and potassium channel blockers.
The antiarrhythmic market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include Pfizer, Merck, Sanofi, Novartis, and GlaxoSmithKline. Other companies in the market include Bristol-Myers Squibb, AstraZeneca, and Boehringer Ingelheim. Show Less Read more
